Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Friday, November 20
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Investing»Verona Pharma CEO David Zaccardelli sells shares worth $633,895 By Investing.com
    Investing

    Verona Pharma CEO David Zaccardelli sells shares worth $633,895 By Investing.com

    October 26, 20243 Mins Read


    David Zaccardelli, President and CEO of Verona Pharma plc (NASDAQ:), recently sold a substantial portion of his holdings in the company. According to a recent SEC filing, Zaccardelli sold a total of 144,816 ordinary shares over three days, from October 23 to October 25, 2024. The sales were executed at prices ranging from $4.375 to $4.3773 per share, amounting to a total value of approximately $633,895.

    These transactions were conducted under a pre-arranged trading plan, as indicated by the filing. Following these sales, Zaccardelli retains ownership of 14,591,736 ordinary shares. Each ordinary share is represented by an American Depositary Share (ADS), with eight ordinary shares per ADS.

    In other recent news, Verona Pharma has made significant strides with the FDA approval and launch of Ohtuvayre, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). The company’s Q2 2024 earnings report revealed a strong financial position, with cash reserves exceeding $400 million. Piper Sandler and H.C. Wainwright have maintained their Overweight and Buy ratings respectively, with a steady price target of $36.00. Wells Fargo, on the other hand, has set a higher target of $50.00, suggesting the market has underestimated the potential of Ohtuvayre.

    Verona Pharma has also partnered with The Ritedose Corporation for the development and manufacturing of Ohtuvayre, and with Nuance Pharma for a Phase 3 clinical trial in China. These partnerships highlight the company’s commitment to advancing COPD treatment and expanding its market reach. The company has initiated patient shipments through specialty pharmacies, targeting approximately 14,500 healthcare providers in the U.S.

    These recent developments reflect Verona Pharma’s ongoing efforts to establish Ohtuvayre in the market, with analysts from Wells Fargo suggesting that the drug could significantly exceed market expectations and potentially surpass $3 billion in peak sales.

    InvestingPro Insights

    Verona Pharma’s recent stock performance adds context to CEO David Zaccardelli’s decision to sell shares. According to InvestingPro data, VRNA has seen a remarkable 183.58% price total return over the past year, and is currently trading near its 52-week high, with the price at 95.06% of its peak. This strong performance may have influenced the timing of the CEO’s stock sale.

    Despite the company’s impressive stock gains, InvestingPro Tips highlight some financial challenges. Verona Pharma is not profitable over the last twelve months, and analysts do not anticipate profitability this year. The company also suffers from weak gross profit margins, which could be a concern for long-term investors.

    On a positive note, VRNA holds more cash than debt on its balance sheet, and its liquid assets exceed short-term obligations. This strong financial position may provide some reassurance to shareholders in light of the CEO’s stock sale.

    For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Verona Pharma, providing a deeper understanding of the company’s financial health and market position.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticlePUC, DHS look to simplify access to utility assistance for families in need
    Next Article Banzai International sees $66,048 stock sale by CP BF lending By Investing.com

    Related Posts

    Investing

    NZD/INR Historical Data | New Zealand Dollar Indian Rupee

    October 30, 2026
    Investing

    GBP 2 Years IRS Interest Rate Swap Bond Chart (Live Data)

    October 27, 2026
    Investing

    USD/CNY Historical Data | US Dollar Chinese Yuan

    October 25, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Property

    Gemdale USA Sells Calabasas Office Building for $69.4M

    February 10, 2025
    Stock Market

    Stock market today: Dow, S&P 500, Nasdaq slide after Nvidia earnings, economic data – Yahoo Finance

    February 27, 2025
    Investing

    EUREP Expansion and the Euro – Going Global

    February 16, 2026
    What's Hot

    Stock Market Highlights 26 December 2025: Markets slide for third straight session as foreign fund outflows drag Sensex 367 points, Nifty slips 99.80 points to 26,042.30

    December 26, 2025

    Garaventa Property Sale Continues To be Ruled Out by City of Livermore | Livermore News

    August 29, 2024

    Aegon to sell UK unit to Standard Life for £2 billion By Investing.com

    April 14, 2026
    Most Popular

    Nifty, Sensex Snap Six-Week Losing Streak; Wipro, Eternal Top Gainers

    August 14, 2025

    XRPL Transactions Hit High as XRP Seen ‘Less Exposed’ to Quantum Threats Than Bitcoin

    April 11, 2026

    Vous avez une idée pour améliorer la vie des gens ? Cette commune près de Rouen vous finance

    March 10, 2025
    Editor's Picks

    Cryptoqueen Zhimin Qian in £5.5billion Bitcoin scam is arrested while still in bed

    November 12, 2025

    Commercial Property: Definition and Profit Potential Explained

    June 1, 2026

    Biggest Stock Market Crashes: Causes, Damage, Impact

    July 19, 2024
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.